|
|
Blood, 1 January 2005, Vol. 105, No. 1, pp. 368-375.
Prepublished online as a Blood First Edition Paper on August 26, 2004; DOI 10.1182/blood-2004-06-2226.
Previous Article | Table of Contents | Next Article 
RED CELLS
Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria
An-Sheng Zhang,
Alex D. Sheftel, and
Prem Ponka
From the Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; the Department of Physiology, McGill University, Montreal, QC, Canada; the Department of Cellular and Developmental Biology, Oregon Health Sciences University, Portland.
In erythroid cells the vast majority of iron (Fe) released from endosomes must cross both the outer and the inner mitochondrial membranes to reach ferrochelatase that inserts Fe into protoporphyrin IX. In the present study, we developed a method whereby a cohort of 59Fe-transferrin (Tf)-laden endosomal vesicles were generated, from which we could evaluate the transfer of 59Fe into mitochondria. Iron chelators, dipyridyl or salicylaldehyde isonicotinoyl hydrazone (SIH), were able to bind the 59Fe when they were present during a 37°C incubation; however, addition of these agents only during lysis at 4°C chelated virtually no 59Fe. Bafilomycin A1 (which prevents endosome acidification) and succinylacetone (an inhibitor of 5-aminolevulinate dehydratase) prevented endosomal 59Fe incorporation into heme. Importantly, both the myosin light chain kinase inhibitor wortmannin and the calmodulin antagonist, N-(6-aminohexyl)-5-chloro-1-naphthalene-sulfonamide (W-7), caused significant inhibition of 59Fe incorporation from 59Fe-Tf-labeled endosomes into heme, suggesting that myosin is required for Tf-vesicle movement. Our results reaffirm the astonishing efficiency of Tf-derived Fe utilization in hemoglobin (Hb)-producing cells and demonstrate that very little of this Fe is present in a chelatable pool. Collectively, these results are congruent with our hypothesis that a transient endosome-mitochondrion interaction mediates iron transfer between these organelles. (Blood. 2005;105:368-375)

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Shvartsman, R. Kikkeri, A. Shanzer, and Z. I. Cabantchik
Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications
Am J Physiol Cell Physiol,
October 1, 2007;
293(4):
C1383 - C1394.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Sheftel, A.-S. Zhang, C. Brown, O. S. Shirihai, and P. Ponka
Direct interorganellar transfer of iron from endosome to mitochondrion
Blood,
July 1, 2007;
110(1):
125 - 132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. C. Gauthier, P. Monzo, T. Gonzalez, A. Doye, A. Oldani, P. Gounon, V. Ricci, M. Cormont, and P. Boquet
Early endosomes associated with dynamic F-actin structures are required for late trafficking of H. pylori VacA toxin
J. Cell Biol.,
April 23, 2007;
177(2):
343 - 354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Sheftel, S. F. Kim, and P. Ponka
Non-heme Induction of Heme Oxygenase-1 Does Not Alter Cellular Iron Metabolism
J. Biol. Chem.,
April 6, 2007;
282(14):
10480 - 10486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Matarrese, L. Falzano, A. Fabbri, L. Gambardella, C. Frank, B. Geny, M. R. Popoff, W. Malorni, and C. Fiorentini
Clostridium difficile Toxin B Causes Apoptosis in Epithelial Cells by Thrilling Mitochondria: INVOLVEMENT OF ATP-SENSITIVE MITOCHONDRIAL POTASSIUM CHANNELS
J. Biol. Chem.,
March 23, 2007;
282(12):
9029 - 9041.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schranzhofer, M. Schifrer, J. A. Cabrera, S. Kopp, P. Chiba, H. Beug, and E. W. Mullner
Remodeling the regulation of iron metabolism during erythroid differentiation to ensure efficient heme biosynthesis
Blood,
May 15, 2006;
107(10):
4159 - 4167.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Kalinowski and D. R. Richardson
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Pharmacol. Rev.,
December 1, 2005;
57(4):
547 - 583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Glickstein, R. Ben El, M. Shvartsman, and Z. I. Cabantchik
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells
Blood,
November 1, 2005;
106(9):
3242 - 3250.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Xu, H. L. Persson, and D. R. Richardson
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
Mol. Pharmacol.,
August 1, 2005;
68(2):
261 - 271.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Najahi-Missaoui and H. A. Dailey
Production and characterization of erythropoietic protoporphyric heterodimeric ferrochelatases
Blood,
August 1, 2005;
106(3):
1098 - 1104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. C. Culotta, M. Yang, and M. D. Hall
Manganese Transport and Trafficking: Lessons Learned from Saccharomyces cerevisiae
Eukaryot. Cell,
July 1, 2005;
4(7):
1159 - 1165.
[Full Text]
[PDF]
|
 |
|
|
|